Dominick Conde analyzes the Supreme Court’s January 20th, 2015 decision in Teva Pharmaceuticals v. Sandoz, which overturned the Federal Circuit’s de novo standard of review for district court claim constructions, and its implications on future patent litigations.
March 2015 | Intellectual Property Today
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.: Where Does Claim Construction Go From Here?
1 min
Related Services
Related Insights
Supreme Court Hears Oral Argument on Whether to Abolish or Modify Assignor Estoppel Doctrine in Patent Cases
Supreme Court Hears Oral Argument on Whether to Abolish or Modify Assignor Estoppel Doctrine in Patent Cases
April 22, 2021
8min
How to Quickly Estimate a Patent's Value Using Discounted Cash Flow
How to Quickly Estimate a Patent's Value Using Discounted Cash Flow
April 07, 2021
6min
Supreme Court Weighs in on Fair Use, Finding Google's Use of Java SE API Is Fair
Supreme Court Weighs in on Fair Use, Finding Google's Use of Java SE API Is Fair
April 05, 2021
3min
Events
Protecting Trade Secrets: Translating Principle Into Practice
Protecting Trade Secrets: Translating Principle Into Practice
May 25, 2021 Los Angeles Intellectual Property Law Association (LAIPLA)
Recent News
Politico Quotes Fred Wagner on DOT’s Review of a Texas Highway Expansion Project
Politico Quotes Fred Wagner on DOT’s Review of a Texas Highway Expansion Project
May 10, 2021
1min
Financial Planning Quotes Lawrence Mandelker on the Biden Administration’s Tax Proposals
Financial Planning Quotes Lawrence Mandelker on the Biden Administration’s Tax Proposals
May 05, 2021
1min
InsuranceNewsNet Quotes Lawrence Mandelker on Maximizing the Benefits of a Life Insurance Policy
InsuranceNewsNet Quotes Lawrence Mandelker on Maximizing the Benefits of a Life Insurance Policy
May 01, 2021
2min